Peter Shaw | Head of Clinical Pharmacogenetics
Merck

Appearances:

Day One @ 11:40

Leveraging pharmacogenetics in drug development

• Application of routine genotyping analyses across the pipeline
• Understanding contribution of ADME PGx in development programs
• Improving benefit-risk considerations by identifying response variants